Biodexa Pharmaceuticals annual diluted eps
Diluted EPSBasic EPS
2015
2016
2017
2022
2023
2024
2025
Biodexa Pharmaceuticals EPS History: Annual & Quarterly (BDRX)
Biodexa Pharmaceuticals's diluted EPS was -£0.00 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -£0.00 | -£0.00 | £0.00 | — |
| 2024 | 2024-12-31 | -£0.00 | -£0.00 | £0.02 | — |
| 2023 | 2023-12-31 | -£0.02 | -£0.02 | £1.53 | — |
| 2022 | 2022-12-31 | -£1.55 | -£1.55 | — | — |
| 2017 | 2017-12-31 | -£31.00 | -£31.00 | -£30.44 | — |
| 2016 | 2016-12-31 | -£0.56 | -£0.56 | -£0.20 | — |
| 2015 | 2015-12-31 | -£0.36 | -£0.36 | — | — |
Biodexa Pharmaceuticals diluted eps trends
Between the periods ended 2015-12-31 and 2025-12-31, Biodexa Pharmaceuticals's diluted eps increased from -£0.36 to -£0.00, a change of £0.36.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...